Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Prognostic Relevance of Steroid Sulfation in Adrenocortical Carcinoma Revealed by Molecular Phenotyping Using High-Resolution Mass Spectrometry Imaging.

Sun N, Kunzke T, Sbiera S, Kircher S, Feuchtinger A, Aichler M, Herterich S, Ronchi CL, Weigand I, Schlegel N, Waldmann J, Fragoso MCV, Whitsett TG, Gill AJ, Fassnacht M, Walch A, Kroiss M.

Clin Chem. 2019 Sep 6. pii: clinchem.2019.306043. doi: 10.1373/clinchem.2019.306043. [Epub ahead of print]

PMID:
31492715
2.

Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma.

Assié G, Jouinot A, Fassnacht M, Libé R, Garinet S, Jacob L, Hamzaoui N, Neou M, Sakat J, de La Villéon B, Perlemoine K, Ragazzon B, Sibony M, Tissier F, Gaujoux S, Dousset B, Sbiera S, Ronchi CL, Kroiss M, Korpershoek E, De Krijger R, Waldmann J, Quinkler M, Haissaguerre M, Tabarin A, Chabre O, Luconi M, Mannelli M, Groussin L, Bertagna X, Baudin E, Amar L, Coste J, Beuschlein F, Bertherat J.

JAMA Oncol. 2019 Jul 11. doi: 10.1001/jamaoncol.2019.1558. [Epub ahead of print]

PMID:
31294750
3.

The neuropeptide receptor subunit RAMP1 constrains the innate immune response during acute pancreatitis in mice.

Jochheim LS, Odysseos G, Hidalgo-Sastre A, Zhong S, Staufer LM, Kroiss M, Kabacaoglu D, Lange S, Engleitner T, Hartmann D, Hüser N, Steiger K, Schmid RM, Holzmann B, von Figura G.

Pancreatology. 2019 Jun;19(4):541-547. doi: 10.1016/j.pan.2019.05.455. Epub 2019 May 11.

PMID:
31109903
4.

A method for the minimally invasive drug monitoring of mitotane by means of volumetric absorptive microsampling for a home-based therapeutic drug monitoring.

Friedl B, Kurlbaum M, Kroiss M, Fassnacht M, Scherf-Clavel O.

Anal Bioanal Chem. 2019 Jul;411(17):3951-3962. doi: 10.1007/s00216-019-01868-1. Epub 2019 May 16.

PMID:
31093700
5.

Plasma steroid metabolome profiling for the diagnosis of adrenocortical carcinoma.

Schweitzer S, Kunz M, Kurlbaum M, Vey J, Kendl S, Deutschbein T, Hahner S, Fassnacht M, Dandekar T, Kroiss M.

Eur J Endocrinol. 2019 Feb 1;180(2):117-125. doi: 10.1530/EJE-18-0782.

PMID:
30481155
6.

Advanced Adrenocortical Carcinoma - What to do when First-Line Therapy Fails?

Megerle F, Kroiss M, Hahner S, Fassnacht M.

Exp Clin Endocrinol Diabetes. 2019 Feb;127(2-03):109-116. doi: 10.1055/a-0715-1946. Epub 2018 Nov 23. Review.

7.

Patterns of Lymph Node Recurrence in Adrenocortical Carcinoma: Possible Implications for Primary Surgical Treatment.

Reibetanz J, Rinn B, Kunz AS, Flemming S, Ronchi CL, Kroiss M, Deutschbein T, Pulzer A, Hahner S, Kocot A, Germer CT, Fassnacht M, Jurowich C.

Ann Surg Oncol. 2019 Feb;26(2):531-538. doi: 10.1245/s10434-018-6999-z. Epub 2018 Nov 15.

PMID:
30443830
8.

Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry.

Kroiss M, Deutschbein T, Schlötelburg W, Ronchi CL, Hescot S, Körbl D, Megerle F, Beuschlein F, Neu B, Quinkler M, Baudin E, Hahner S, Heidemeier A, Fassnacht M.

Exp Clin Endocrinol Diabetes. 2018 Nov 14. doi: 10.1055/a-0747-5571. [Epub ahead of print]

PMID:
30428495
9.

Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane.

Sbiera S, Kendl S, Weigand I, Sbiera I, Fassnacht M, Kroiss M.

Mol Cell Endocrinol. 2019 Jan 15;480:36-41. doi: 10.1016/j.mce.2018.10.009. Epub 2018 Oct 10.

PMID:
30315857
10.

Abiraterone Acetate for Cushing Syndrome: Study in a Canine Primary Adrenocortical Cell Culture Model.

Sanders K, de Wit WL, Mol JA, Kurlbaum M, Kendl S, Kroiss M, Kooistra HS, Galac S.

Endocrinology. 2018 Nov 1;159(11):3689-3698. doi: 10.1210/en.2018-00588.

PMID:
30219917
11.

Volumetric and texture analysis of pretherapeutic 18F-FDG PET can predict overall survival in medullary thyroid cancer patients treated with Vandetanib.

Werner RA, Bundschuh RA, Higuchi T, Javadi MS, Rowe SP, Zsótér N, Kroiss M, Fassnacht M, Buck AK, Kreissl MC, Lapa C.

Endocrine. 2019 Feb;63(2):293-300. doi: 10.1007/s12020-018-1749-3. Epub 2018 Sep 11.

12.

Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication.

Lippert J, Appenzeller S, Liang R, Sbiera S, Kircher S, Altieri B, Nanda I, Weigand I, Gehrig A, Steinhauer S, Riemens RJM, Rosenwald A, Müller CR, Kroiss M, Rost S, Fassnacht M, Ronchi CL.

J Clin Endocrinol Metab. 2018 Dec 1;103(12):4511-4523. doi: 10.1210/jc.2018-01348.

PMID:
30113656
13.

Enzyme autoinduction by mitotane supported by population pharmacokinetic modelling in a large cohort of adrenocortical carcinoma patients.

Arshad U, Taubert M, Kurlbaum M, Frechen S, Herterich S, Megerle F, Hamacher S, Fassnacht M, Fuhr U, Kroiss M.

Eur J Endocrinol. 2018 Oct 16;179(5):287-297. doi: 10.1530/EJE-18-0342.

PMID:
30087117
14.

A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus.

Fenske W, Refardt J, Chifu I, Schnyder I, Winzeler B, Drummond J, Ribeiro-Oliveira A Jr, Drescher T, Bilz S, Vogt DR, Malzahn U, Kroiss M, Christ E, Henzen C, Fischli S, Tönjes A, Mueller B, Schopohl J, Flitsch J, Brabant G, Fassnacht M, Christ-Crain M.

N Engl J Med. 2018 Aug 2;379(5):428-439. doi: 10.1056/NEJMoa1803760.

15.

Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma.

Richter S, Gieldon L, Pang Y, Peitzsch M, Huynh T, Leton R, Viana B, Ercolino T, Mangelis A, Rapizzi E, Menschikowski M, Aust D, Kroiss M, Beuschlein F, Gudziol V, Timmers HJ, Lenders J, Mannelli M, Cascon A, Pacak K, Robledo M, Eisenhofer G, Klink B.

Genet Med. 2019 Mar;21(3):705-717. doi: 10.1038/s41436-018-0106-5. Epub 2018 Jul 27.

16.

Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma.

Megerle F, Herrmann W, Schloetelburg W, Ronchi CL, Pulzer A, Quinkler M, Beuschlein F, Hahner S, Kroiss M, Fassnacht M; German ACC Study Group.

J Clin Endocrinol Metab. 2018 Apr 1;103(4):1686-1695. doi: 10.1210/jc.2017-02591.

PMID:
29452402
17.

High-Resolution Tissue Mass Spectrometry Imaging Reveals a Refined Functional Anatomy of the Human Adult Adrenal Gland.

Sun N, Wu Y, Nanba K, Sbiera S, Kircher S, Kunzke T, Aichler M, Berezowska S, Reibetanz J, Rainey WE, Fassnacht M, Walch A, Kroiss M.

Endocrinology. 2018 Mar 1;159(3):1511-1524. doi: 10.1210/en.2018-00064.

18.

Functional Implications of LH/hCG Receptors in Pregnancy-Induced Cushing Syndrome.

Plöckinger U, Chrusciel M, Doroszko M, Saeger W, Blankenstein O, Weizsäcker K, Kroiss M, Hauptmann K, Radke C, Pöllinger A, Tiling N, Steinmüller T, Huhtaniemi I, Quinkler M, Bertherat J, Lacroix A, Rahman N.

J Endocr Soc. 2017 Jan 12;1(1):57-71. doi: 10.1210/js.2016-1021. eCollection 2017 Jan 1.

19.

Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors.

Henning JEK, Deutschbein T, Altieri B, Steinhauer S, Kircher S, Sbiera S, Wild V, Schlötelburg W, Kroiss M, Perotti P, Rosenwald A, Berruti A, Fassnacht M, Ronchi CL.

J Clin Endocrinol Metab. 2017 Nov 1;102(11):4323-4332. doi: 10.1210/jc.2017-01624.

PMID:
29092062
20.

Predictive Value of 18F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with Vandetanib.

Werner RA, Schmid JS, Higuchi T, Javadi MS, Rowe SP, Märkl B, Aulmann C, Fassnacht M, Kroiss M, Reiners C, Buck AK, Kreissl MC, Lapa C.

J Nucl Med. 2018 May;59(5):756-761. doi: 10.2967/jnumed.117.199778. Epub 2017 Oct 12.

21.

Outcome after resection of Adrenocortical Carcinoma liver metastases: a retrospective study.

Baur J, Büntemeyer TO, Megerle F, Deutschbein T, Spitzweg C, Quinkler M, Nawroth P, Kroiss M, Germer CT, Fassnacht M, Steger U; German Adrenocortical Carcinoma Study Group.

BMC Cancer. 2017 Aug 4;17(1):522. doi: 10.1186/s12885-017-3506-z.

22.

Phaeochromocytoma in multiple endocrine neoplasia type 2: RET codon-specific penetrance and changes in management during the last four decades.

Mucha L, Leidig-Bruckner G, Frank-Raue K, Bruckner T, Kroiss M, Raue F; German study group for rare thyroid cancer.

Clin Endocrinol (Oxf). 2017 Oct;87(4):320-326. doi: 10.1111/cen.13386. Epub 2017 Jun 30. Review.

PMID:
28605116
23.

Cortisol-related metabolic alterations assessed by mass spectrometry assay in patients with Cushing's syndrome.

Di Dalmazi G, Quinkler M, Deutschbein T, Prehn C, Rayes N, Kroiss M, Berr CM, Stalla G, Fassnacht M, Adamski J, Reincke M, Beuschlein F.

Eur J Endocrinol. 2017 Aug;177(2):227-237. doi: 10.1530/EJE-17-0109. Epub 2017 May 31.

PMID:
28566446
24.

Prospective identification of hematopoietic lineage choice by deep learning.

Buggenthin F, Buettner F, Hoppe PS, Endele M, Kroiss M, Strasser M, Schwarzfischer M, Loeffler D, Kokkaliaris KD, Hilsenbeck O, Schroeder T, Theis FJ, Marr C.

Nat Methods. 2017 Apr;14(4):403-406. doi: 10.1038/nmeth.4182. Epub 2017 Feb 20.

25.

DNA Methylation Is an Independent Prognostic Marker of Survival in Adrenocortical Cancer.

Jouinot A, Assie G, Libe R, Fassnacht M, Papathomas T, Barreau O, de la Villeon B, Faillot S, Hamzaoui N, Neou M, Perlemoine K, Rene-Corail F, Rodriguez S, Sibony M, Tissier F, Dousset B, Sbiera S, Ronchi C, Kroiss M, Korpershoek E, de Krijger R, Waldmann J, K D, Bartsch, Quinkler M, Haissaguerre M, Tabarin A, Chabre O, Sturm N, Luconi M, Mantero F, Mannelli M, Cohen R, Kerlan V, Touraine P, Barrande G, Groussin L, Bertagna X, Baudin E, Amar L, Beuschlein F, Clauser E, Coste J, Bertherat J.

J Clin Endocrinol Metab. 2017 Mar 1;102(3):923-932. doi: 10.1210/jc.2016-3205.

PMID:
27967600
26.

Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany.

Wendler J, Kroiss M, Gast K, Kreissl MC, Allelein S, Lichtenauer U, Blaser R, Spitzweg C, Fassnacht M, Schott M, Führer D, Tiedje V.

Eur J Endocrinol. 2016 Dec;175(6):521-529.

PMID:
27926471
27.

Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients.

Bluemel C, Hahner S, Heinze B, Fassnacht M, Kroiss M, Bley TA, Wester HJ, Kropf S, Lapa C, Schirbel A, Buck AK, Herrmann K.

Clin Nucl Med. 2017 Jan;42(1):e29-e34.

PMID:
27819856
28.

Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells.

Kroiss M, Sbiera S, Kendl S, Kurlbaum M, Fassnacht M.

Horm Cancer. 2016 Dec;7(5-6):345-355. Epub 2016 Sep 8.

PMID:
27631436
29.

Inhibition of Cholesterol Esterification in the Adrenal Gland by ATR101/PD132301-2, A Promising Case of Drug Repurposing.

Kroiss M, Fassnacht M.

Endocrinology. 2016 May;157(5):1719-21. doi: 10.1210/en.2016-1210. No abstract available.

PMID:
27149038
30.

Assessment of tumor heterogeneity in treatment-naïve adrenocortical cancer patients using (18)F-FDG positron emission tomography.

Werner RA, Kroiss M, Nakajo M, Mügge DO, Hahner S, Fassnacht M, Schirbel A, Bluemel C, Higuchi T, Papp L, Zsótér N, Buck AK, Bundschuh RA, Lapa C.

Endocrine. 2016 Sep;53(3):791-800. doi: 10.1007/s12020-016-0970-1. Epub 2016 May 2.

PMID:
27138903
31.

The adrenal specific toxicant mitotane directly interacts with lipid membranes and alters membrane properties depending on lipid composition.

Scheidt HA, Haralampiev I, Theisgen S, Schirbel A, Sbiera S, Huster D, Kroiss M, Müller P.

Mol Cell Endocrinol. 2016 Jun 15;428:68-81. doi: 10.1016/j.mce.2016.03.022. Epub 2016 Mar 18.

PMID:
27002491
32.

Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide.

Kroiss M, Deutschbein T, Schlötelburg W, Ronchi CL, Neu B, Müller HH, Quinkler M, Hahner S, Heidemeier A, Fassnacht M; German Adrenocortical Carcinoma Study Group.

Horm Cancer. 2016 Jun;7(3):211-8. doi: 10.1007/s12672-016-0260-7. Epub 2016 Mar 9.

PMID:
26961793
33.

Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.

Kroiss M, Plonné D, Kendl S, Schirmer D, Ronchi CL, Schirbel A, Zink M, Lapa C, Klinker H, Fassnacht M, Heinz W, Sbiera S.

Eur J Endocrinol. 2016 Mar;174(3):343-53. doi: 10.1530/EJE-15-0946. Epub 2015 Dec 15.

PMID:
26671975
34.

Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study.

Libé R, Borget I, Ronchi CL, Zaggia B, Kroiss M, Kerkhofs T, Bertherat J, Volante M, Quinkler M, Chabre O, Bala M, Tabarin A, Beuschlein F, Vezzosi D, Deutschbein T, Borson-Chazot F, Hermsen I, Stell A, Fottner C, Leboulleux S, Hahner S, Mannelli M, Berruti A, Haak H, Terzolo M, Fassnacht M, Baudin E; ENSAT network.

Ann Oncol. 2015 Oct;26(10):2119-25. doi: 10.1093/annonc/mdv329.

35.

Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells.

Sbiera S, Leich E, Liebisch G, Sbiera I, Schirbel A, Wiemer L, Matysik S, Eckhardt C, Gardill F, Gehl A, Kendl S, Weigand I, Bala M, Ronchi CL, Deutschbein T, Schmitz G, Rosenwald A, Allolio B, Fassnacht M, Kroiss M.

Endocrinology. 2015 Nov;156(11):3895-908. doi: 10.1210/en.2015-1367. Epub 2015 Aug 25.

PMID:
26305886
36.

Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome.

Ronchi CL, Sbiera S, Altieri B, Steinhauer S, Wild V, Bekteshi M, Kroiss M, Fassnacht M, Allolio B.

Endocr Relat Cancer. 2015 Aug;22(4):531-43. doi: 10.1530/ERC-15-0163. Epub 2015 May 15.

PMID:
25979380
37.

Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study.

Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD.

Lancet Oncol. 2015 Apr;16(4):426-35. doi: 10.1016/S1470-2045(15)70081-1. Epub 2015 Mar 18.

38.

Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection.

Beuschlein F, Weigel J, Saeger W, Kroiss M, Wild V, Daffara F, Libé R, Ardito A, Al Ghuzlan A, Quinkler M, Oßwald A, Ronchi CL, de Krijger R, Feelders RA, Waldmann J, Willenberg HS, Deutschbein T, Stell A, Reincke M, Papotti M, Baudin E, Tissier F, Haak HR, Loli P, Terzolo M, Allolio B, Müller HH, Fassnacht M.

J Clin Endocrinol Metab. 2015 Mar;100(3):841-9. doi: 10.1210/jc.2014-3182. Epub 2015 Jan 5.

39.

Measurements of plasma metanephrines by immunoassay vs liquid chromatography with tandem mass spectrometry for diagnosis of pheochromocytoma.

Weismann D, Peitzsch M, Raida A, Prejbisz A, Gosk M, Riester A, Willenberg HS, Klemm R, Manz G, Deutschbein T, Kroiss M, Därr R, Bidlingmaier M, Januszewicz A, Eisenhofer G, Fassnacht M.

Eur J Endocrinol. 2015 Mar;172(3):251-60. doi: 10.1530/EJE-14-0730. Epub 2014 Dec 1.

PMID:
25452465
40.

CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma.

Ronchi CL, Sbiera S, Volante M, Steinhauer S, Scott-Wild V, Altieri B, Kroiss M, Bala M, Papotti M, Deutschbein T, Terzolo M, Fassnacht M, Allolio B.

PLoS One. 2014 Aug 21;9(8):e105855. doi: 10.1371/journal.pone.0105855. eCollection 2014.

41.

QUANTIFYING ALTERNATIVE SPLICING FROM PAIRED-END RNA-SEQUENCING DATA.

Rossell D, Stephan-Otto Attolini C, Kroiss M, Stöcker A.

Ann Appl Stat. 2014 Mar;8(1):309-330.

42.

Integrated genomic characterization of adrenocortical carcinoma.

Assié G, Letouzé E, Fassnacht M, Jouinot A, Luscap W, Barreau O, Omeiri H, Rodriguez S, Perlemoine K, René-Corail F, Elarouci N, Sbiera S, Kroiss M, Allolio B, Waldmann J, Quinkler M, Mannelli M, Mantero F, Papathomas T, De Krijger R, Tabarin A, Kerlan V, Baudin E, Tissier F, Dousset B, Groussin L, Amar L, Clauser E, Bertagna X, Ragazzon B, Beuschlein F, Libé R, de Reyniès A, Bertherat J.

Nat Genet. 2014 Jun;46(6):607-12. doi: 10.1038/ng.2953. Epub 2014 Apr 20.

PMID:
24747642
43.

EJE prize 2014: current and evolving treatment options in adrenocortical carcinoma: where do we stand and where do we want to go?

Ronchi CL, Kroiss M, Sbiera S, Deutschbein T, Fassnacht M.

Eur J Endocrinol. 2014 Jul;171(1):R1-R11. doi: 10.1530/EJE-14-0273. Epub 2014 Apr 8. Review.

PMID:
24714084
44.

No endogenous ouabain is detectable in human plasma by ultra-sensitive UPLC-MS/MS.

Baecher S, Kroiss M, Fassnacht M, Vogeser M.

Clin Chim Acta. 2014 Apr 20;431:87-92. doi: 10.1016/j.cca.2014.01.038. Epub 2014 Feb 7.

PMID:
24508998
45.

Thyroid function, cardiovascular events, and mortality in diabetic hemodialysis patients.

Drechsler C, Schneider A, Gutjahr-Lengsfeld L, Kroiss M, Carrero JJ, Krane V, Allolio B, Wanner C, Fassnacht M.

Am J Kidney Dis. 2014 Jun;63(6):988-96. doi: 10.1053/j.ajkd.2013.10.009. Epub 2013 Dec 4.

PMID:
24315768
46.

Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer.

Berruti A, Fassnacht M, Haak H, Else T, Baudin E, Sperone P, Kroiss M, Kerkhofs T, Williams AR, Ardito A, Leboulleux S, Volante M, Deutschbein T, Feelders R, Ronchi C, Grisanti S, Gelderblom H, Porpiglia F, Papotti M, Hammer GD, Allolio B, Terzolo M.

Eur Urol. 2014 Apr;65(4):832-8. doi: 10.1016/j.eururo.2013.11.006. Epub 2013 Nov 14.

47.

Update in adrenocortical carcinoma.

Fassnacht M, Kroiss M, Allolio B.

J Clin Endocrinol Metab. 2013 Dec;98(12):4551-64. doi: 10.1210/jc.2013-3020. Epub 2013 Sep 30. Review.

PMID:
24081734
48.

Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.

Terzolo M, Baudin AE, Ardito A, Kroiss M, Leboulleux S, Daffara F, Perotti P, Feelders RA, deVries JH, Zaggia B, De Francia S, Volante M, Haak HR, Allolio B, Al Ghuzlan A, Fassnacht M, Berruti A.

Eur J Endocrinol. 2013 Jul 29;169(3):263-70. doi: 10.1530/EJE-13-0242. Print 2013 Sep.

49.

Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatography-tandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma.

Peitzsch M, Prejbisz A, Kroiß M, Beuschlein F, Arlt W, Januszewicz A, Siegert G, Eisenhofer G.

Ann Clin Biochem. 2013 Mar;50(Pt 2):147-55. doi: 10.1258/acb.2012.012112.

PMID:
23512172
50.

Is there a role for laparoscopic adrenalectomy in patients with suspected adrenocortical carcinoma? A critical appraisal of the literature.

Jurowich C, Fassnacht M, Kroiss M, Deutschbein T, Germer CT, Reibetanz J.

Horm Metab Res. 2013 Feb;45(2):130-6. doi: 10.1055/s-0032-1331743. Epub 2013 Jan 11. Review.

PMID:
23315992

Supplemental Content

Loading ...
Support Center